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ABSTRACT
A cyclooxygenase-2 (COX-2) inhibitor celecoxib has been previously reported to have cytotoxic activities
towards gastric, prostate, ovarian, colon and breast cancer cell lines. This article reports that the cytotoxic activities
of celecoxib could be resulted from its activity as a potent ligand for estrogen receptor alpha (ERα). Aided by 
molecular docking simulations, an in silico test to examine whether celecoxib is a ligand for estrogen receptor alpha
(ERα) was performed followed by in vitro test employing cytotoxic assay using 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide (MTT) method. The compound was extracted from Celebrex®. Measured by using UV
spectrophotometric method at 255.5 nm, it was identified that the content of celecoxib was 102.15 mg/271.48 mg
capsule content. The in silico test indicated that celecoxib is a potent ligand for ERα. This finding was confirmed 
experimentally by an in vitro test that celecoxib has a comparable activity as an ERα ligand to tamoxifen, a drug of 
choice for breast cancer treatment.
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ABSTRAK
Obat anti-inflamasi celecoxib, sebuah inhibitor siklooksigenase (COX-2), diketahui memiliki aktivitas sitotoksik
pada sel kanker saluran pencernaan, prostat, indung telur dan payudara. Dalam artikel ini disampaikan bahwa
aktivitas sitotoksik tersebut diduga berkaitan dengan aktivitas senyawa tersebut sebagai ligan pada reseptor
estrogen alfa (REα). Bertulangpunggungkan simulasi penambatan molekuler, uji in silico untuk mengevaluasi
aktivitas celecoxib sebagai ligan pada ERα yang diverifikasi secara in vitro melalui uji sitotoksik dengan metode 3-
[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT). Senyawa uji celecoxib diekstrak dari kapsul
Celebrex® yang ditetapkan kadarnya dengan metode spektrofotometri UV pada panjang gelombang 255,5 nm.
Diketahui bahwa kadar celecoxib dalam kapsul adalah 102,15 mg tiap 271,48 mg isi kapsul. Hasil uji in silico
mengindikasikan bahwa celecoxib merupakan ligan poten pada ERα. Hasil ini dikonfirmasi secara in vitro bahwa
celecoxib memiliki aktivitas sebagai ligan pada ERα dengan potensi serupa dengan tamoxifen, obat pilihan untuk 
kanker payudara.
Kata Kunci: siklooksigenase-2; reseptor estrogen alfa; penambatan molekuler; celecoxib
INTRODUCTION
Celecoxib (Fig. 1A) is widely marketed as a
selective cyclooxygenase-2 (COX-2) anti-inflammatory
drug and has proven to be a blockbuster drug [1-2].
Interestingly, it shows some indications of its role in the
cancer pathophysiology, especially in the apoptosis
pathways [3]. Celecoxib was reported to play an
important role in inhibiting the proliferation of the NPC
cell lines [3-4], modulating the expression of Bcl-2
family members and mitochondria-mediated apoptosis
[3,5], regulating Survivin, Mcl-1, Bcl-2 and Cyclin D1
[3–5], and inducing apoptosis and cell-cycle arrest at the
G(0)/G(1) checkpoint [3-4]. As a COX-2 inhibitor [2,6-7],
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Fig 1. Structures of celecoxib (A) and tamoxifen (B)
celecoxib shows anticancer properties in some cancer
cell lines including colon cancer [8] and prostate cancer
[9]. However, this drug suppresses also another COX-2
independent molecular pathway in prostate cancer [9].
Celecoxib is suggested also to have activities against
breast cancer since breast is a tissue involved in COX-2
up regulation [10]. Crosstalk of COX-2 with estrogen
receptor alpha (ERα) pathway was suggested to play an 
important role in the activities of celecoxib in the breast
cancer pathophysiology [11].
An ERα antagonist tamoxifen (Fig. 1B) is the 
standard adjuvant for postmenopausal women with
hormone-receptor-positive early breast cancer [12].
Notably, tamoxifen is a prodrug since it is metabolized to
some active metabolites (e.g., 4-hydroxytamoxifen and
N-desmethyl-4-hydroxy-tamoxifen) in the liver [13]. The
affinity of the metabolites to ERα is 30-100 fold higher 
compared to tamoxifen in its original form [13]. In a
recent prospective structure-based virtual screening
(SBVS) campaign on the ZINC drug database (ZDD)
[14] to discover ligands for ERα [15], celecoxib 
(ZINC02570895 [14]) together with 67 other drugs were
identified as potent ligands for ERα [15]. It is therefore of 
a considerable and timely interest to verify whether
celecoxib is a potent ligand for ERα. 
In this article, exhaustive SBVS campaigns
followed by in vitro tests to verify whether celecoxib a
potent ligand for ERα are presented. The research 
aimed to employ computer-aided drug repurposing
strategy [16] to verify the activity of celecoxib as a potent
ligand for ERα. The SBVS protocol used to perform in
silico tests was initially constructed and retrospectively
validated by Anita et al. [17] to identify ERα antagonists 
[18]. By incorporating PyPLIF [19], subsequently the
protocol was re-validated and and reported that the
protocol employing PyPLIF has a significantly better
quality [19-21]. The in silico screenings followed by in
vitro tests employing tamoxifen as the reference
compound has confirmed that celecoxib is a potent
ligand for ERα.
EXPERIMENTAL SECTION
Materials
Celecoxib in three dimensional (3D) mode in the
form of a mol2 file was obtained from the ZINC database
[14]. The ZINC code of celecoxib was ZINC02570895
[14,22]. Configuration files to perform in silico tests to
identify celecoxib as ERα ligand by using PLANTS 
docking software were obtained from Anita et al. [17]:
(i) The virtual target protein.mol2, (ii) the conserved
water molecule water.mol2, and (iii) the configuration
files to run PLANTS docking software plants.config.
Configuration files to perform protein-ligand interaction
fingerprints (PLIF) identification using PyPLIF were
obtained from Radifar et al. [19]: (i) The configuration
file to run PyPLIF config.txt, (ii) the virtual reference
structure OHT.mol2, and (iii) the virtual binding pocket
residues PLANTSactiveSiteResidues.mol2.
Celecoxib standard was purchased from Sigma-
Aldrich. Sample was prepared from Celebrex® (Pfizer)
contain 100 mg celecoxib dissolved in dimethyl
sulfoxide (DMSO) Merck®. MCF-7 breast cancer cell
line was derived from Parasitology Laboratory, Faculty
of Medicine, Universitas Gadjah Mada, Yogyakarta,
Indonesia. Dulbecco's Modified Eagle Medium (DMEM)
(Gibco) as culture medium was purcashed from Gibco.
Cytotoxic assay was performed using 3-[4,5-
dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide
(MTT) (Sigma). Sodium dodecyl sulphate as stopper
reagent was obtained from Merck. Tamoxifen as the
reference compound in DMEM was provided by
Setiawati et al. [23]. This research used US BIO ERα 
primary antibody [23]. All culture plates used in this
study were Iwaki and all tips were purchased from
Biologix.
Instrumentation and Computation
Instrumentation used in this study was Shimadzu
UV-1800 spectrophotometer, cuvette Hellma, Retsch
tipe T460 No V935922013 EY ultrasonicator, Scaltec
SBC 22 (max 60/210 g, min 0.001 g, d = 0.01/0.1 mg)
analytical balance, and Socorex micropipette.
Computational medicinal chemistry applications used in
this research were: PLANTS docking software version
1.2 (PLANTS1.2) [24, 25] to perform molecular docking
simulations, R computational statistics software version
3.1.2 to perform statistical tests [26] and PyPLIF
[19,27] to identify PLIF. All calculations and
computational simulations were performed on a Linux
(Ubuntu 12.04 LTS) machine with Intel(R) Xeon(R) CPU
E31220 (@ 3.10 GHz) as the processors and 8.00 GB
of RAM.
Procedure
Virtual screening on celecoxib as ligand for ERα 
The previously published procedure by Anita et al.
[17] was employed to dock celecoxib to ERα binding 
pocket three times [17,20]. The docked poses resulted
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in the molecular docking simulations were subsequently
subjected to PyPLIF to identify their PLIF [19]. Only
docking poses whose bitstring of 103 is 1 were selected
[19]. From the remaining poses, the best pose of each
run was selected as the pose with the best Tanimoto
coefficient similarity on the PLIF compared to the PLIF of
the co-crystal ligand 4-hydroxytamoxifen (Tc-PLIF)
[19,24] of all three independent runs. This procedure
was performed 1000 times independently. The Tc-PLIF
values of all selected poses from those 1000
independent run were subjected to a relevant statistical
test to examine whether the Tc-PLIF values were
statistically higher or equal to the Tc-PLIF standard
0.720 [19] in level of confidence of 95% [26].
Determination of celecoxib in Celebrex®
Standard solution preparation: A celecoxib stock
solution was obtained by weighing 0.1520 mg of
celecoxib standard accurately into a 1 mL vial, dissolved,
and diluted to volume with DMSO. The intermediate
solution was obtained by transferring 0.8 mL of celecoxib
stock solution into a 5 mL volumetric flask, dissolved,
and diluted to volume with DMSO. The calibration
standard solution of celecoxib was obtained by
transferring 200, 300, 400, 500, 600, and 700 µL of
intermediate solution of celecoxib into 5 mL volumetric
flask and dilute to volume with DMSO. Selection of
wavelength: The maximum absorption wavelength of
celecoxib was determined at the beginning of the study
by scanning the standard solution at 200-400 nm. The
maximum absorption wavelength was determined and
used for the next determination. Sample preparation:
Twenty capsules of Celebrex® were accurately weighed.
An equivalent amount of 50 mg of the drug was taken
and dissolved in DMSO and filtered; volume was made
up to 25 mL. The sample solution was obtained by
transferring 10 µL of stock sample solution into a 10 mL
volumetric flask, dissolved, and diluted to volume with
DMSO.
MTT cytotoxic assay and immunocytostaining of
ERα 
MCF-7 cells were cultured until confluent in DMEM
then 5 x 103 cells were seeded into 96-well microplate
and incubated in 37 °C and 5% CO2 for 24 h. Celecoxib
as stock solution was prepared by dissolving the content
of Celebrex® capsules in DMSO. Then, DMEM was
removed and a series concentration of celecoxib in
DMEM (5.00, 10.00, 25.00, 50.00, 75.00, and
100.00 µM) were added into 96-well plate 100 μL each 
and incubated in the same as previous condition for
24 h. Each concentration was assayed triplo (n = 3). In
the end of incubation time, DMEM was removed from
cells and 100 μL DMEM containing 5 mg/mL MTT was 
added into well plate. The plate was incubated for 4 h,
Fig 2. The histogram of all Tc-PLIF values resulted in
docking using PLANTS1.2 followed by re-scoring using
PyPLIF of celecoxib to ERα 
then 100 μL of 10% SDS was added to each well to 
dissolve crystal formazan. The 96-well microplate was
incubated for 24 h in dark room. Formazan crystals
were measured by ELISA reader using 595 nm
wavelengths. The half-maximal inhibitory concentration
(IC50) value was calculated using four parameters
logistic regression by employing R computational
statistics software version 3.1.2 [26,28]. Similar
procedures were subjected to a series concentration of
tamoxifen in DMEM (5.00, 10.00, 25.00, 40.00, 50.00,
and 100.00 µM) as the reference compound [23]. By
employing the method of ERα immunocytostaining 
published previously [23], the expression of ERα after 
adding celecoxib 30 µM was examined compared to
the expression of ERα after adding tamoxifen 24 µM. 
RESULT AND DISCUSSION
This research aimed to examine whether a widely
used and well-known anti-inflammatory compound
celecoxib is also a potent ligand for ERα. The 
identification of celecoxib as a potential ligand for ERα 
was performed by employing computational chemistry
method, which was subsequently confirmed by in vitro
tests. This approach can serve as an example of
computer-aided drug repurposing in discovery of novel
ligands for ERα. 
The in silico tests resulted in Tc-PLIF values of
0.654 to 0.792 with mean (standard deviation) value of
0.728 (0.024). The histogram of all 1000 Tc-PLIF
values (Fig. 2) indicates that the data is not normally
distributed, which was confirmed by performing
Shapiro-Wilk test (p-value < 0.05). Since the data was
not normally distributed, one sample Wilcoxon test was
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performed instead of one sample t-test to examine
whether the Tc-PLIF values are equal or higher than the
reference Tc-PLIF value (0.720) [19] (H0) or the Tc-PLIF
values are less than the reference Tc-PLIF value (Hi).
The Wilcoxon test resulted in p-value of 1. This means
that at the 95% level of confidences, the Tc-PLIF values
are equal or better than 0.720 statistically. This result
indicated that celecoxib is a potent ligand for ERα 
[1,3,17,19,21]. In vitro tests to confirm these in silico
results were therefore required [17,19,29-36].
In this study, in vitro tests serve as the verification
of the in silico test results [30-34,37-39]. On the other
hand, in silico approaches could assist in the explanation
of in vitro tests [35,40-47]. Very recently, the virtual
screening protocol mainly referred in this study [17,19]
was retrospectively re-validated [20] using the newest
benchmarking dataset provided by Mysinger et al. [36].
The retrospective re-validation resulted in a better
parameter that increased the confidence to further
examine celecoxib as a ligand for ERα [20]. However, 
the cutoff value used in this study (Tc-PLIF value of
0.720) was the one suggested by Radifar et al. [19]
since the retrospective validation showed a better
parameter as a virtual screening protocol to identify
potent ERα in an early enrichment (at 1% false positives) 
compared to the retrospective validation by Setiawati et
al. [20]. Unfortunately, the quality of both virtual
screening protocols to identify ERα ligands globally (at 
100% false positives) could not be compared since
Radifar et al. [19] did not provide the value. In fact,
combined scoring functions using both scoring functions
from PLANTS1.2 (ChemPLP) [24] and PLIF-based
scoring functions [7,19,21,48] are highly recommended
recently [32,49,50]. On the other hand, both
benchmarking datasets [18,36] requires potent ligands
with IC50 value ≤ 1 µM, which decreases the predictive 
ability of the VS protocols to identify moderate ligands
(IC50 values of 1 mM to 1 µM) [17,19-21,23].
Since the approach presented in this article was
aimed to employ computer-aided drug repurposing
strategies, Celebrex® containing 100 mg celecoxib was
employed instead of pure celecoxib. By using UV
spectrophotometric method, the amount of celecoxib in
Celebrex® was determined [51]. Quantification of drug
substance using spectrophotometer was carried out by
preparing solution in transparent solvent and
measuring its absorbance at suitable wavelength [51].
Different with Revathi et al. [51] which used chloroform
as solvent with detection wavelength at 255 nm, the
standard solutions of celecoxib (1.46, 1.95, and
2.43 µg/mL) in this study were dissolved in DMSO. The
solutions were scanned at the wavelength region of
210-400 nm since the nature of the solvent could alter
the position of the spectral peaks [52-53]. The
maximum absorption wavelength of 255.5 nm was
found. Six points calibration curve were subsequently
obtained in a concentration range from
0.97-3.40 µg/mL for celecoxib. The response of the
drug was found to be linear in the investigation
concentration range and the linear regression equation
was y = 0.047x + 0.127 with correlation coefficient
0.9929, which was considered as statistically
acceptable since the experimental value of the
coefficient of correlation (r) was larger than the
Fig 3. Dose response curves for celecoxib and
tamoxifen effect on MCF-7 cell viability
Table 1. Effect of celecoxib and tamoxifen on MCF-7 cell viability after 24 h incubation
Celecoxib Tamoxifen
Concentration (µM) Percentage of MCF-7 viability
(mean ± SEM)
Concentration (µM) Percentage of MCF-7 viability
(mean ± SEM)
100 5.93 ± 0.23 100 15.67 ± 4.00
75 44.54 ± 4.33 50 19.90 ± 3.75
50 77.58 ± 4.61 40 53.46 ± 1.77
25 102.28 ± 2.45 25 84.33 ± 2.68
10 88.98 ± 3.31 10 85.38 ± 0.58
5 97.87 ± 4.47 5 86.83 ± 2.31
IC50 value of celecoxib = 94.06 ± 14.30 µM
R2 of the logistic regression model = 0.983*)
IC50 value of tamoxifen = 40.78 ± 0.48 µM
R2 of the logistic regression model = 0.999*)
*) The R2 value of both models show that the models are acceptable to calculate the IC50 value since the values are larger than
the tabulated ones for the given number of determinations (n = 6; R² = 0.658) at the 95% level of confidences [44,54]
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Fig 4. The ERα expression using immunocytochemistry method observed under light microscope using 400x 
magnification [23]. (A) Untreated cells; (B) Untreated cells without antibody; (C) Trated with celecoxib (30 µM); and
(D) Treated with tamoxifen (24 µM). Symbol “ ” points the expressed ERα [23] 
tabulated one for the given number of determinations (n
= 6; r = 0.811) at the 95% level of confidences [54].
Celecoxib concentrations in six determinations
were 36.93, 37.32, 38.62, 37.58, 38.2, and 37.09%
(w/w), respectively. The mean (standard deviation) of the
concentrations was 37.67 (0.67)% (w/w) or 102.15 mg
celecoxib in 271.48 mg capsule content. Since the
percent relative standard deviation (RSD) obtained on
the six determinations of celecoxib was 1.78%, the
precision was considered as acceptable (RSD < 7.3%)
[52,55].
After determining the celecoxib content in the
Celebrex® capsules sample, the cytotoxic activity of
celecoxib against MCF-7 cell line was subsequently
evaluated. The cell line is one of the established cell line
to examine the activity of compounds as ligands for ERα 
[20,23,56-57]. Celecoxib treatment on MCF-7 cells
changed both of cell viability and morphology. The
compound showed strong cytotoxic activity towards
MCF-7 cell line with IC50 (standard error of measurement
(SEM)) value of 94.06 (14.30) µM, while tamoxifen as
the reference compound showed IC50 (SEM) value of
40.78 (0.48) µM (Table 1; Fig. 3). Since the Shapiro-Wilk
normality test show that the data were normally
distributed but the variance were not homogen, Welch
two sample t-test were performed to examine whether
the IC50 values of celecoxib were different to the IC50
values of tamoxifen (Hi) or not (H0). The Welch two
sample t-test showed that at the 95% level of
confidences the IC50 values of celecoxib were
statistically not different to the IC50 values of tamoxifen
(p-value of 0.065). Moreover, the IC50 value of celecoxib
is in the same micromolar range with the IC50 value of
tamoxifen. These results are inline with the results from
the in silico tests that celecoxib is a potent ligand for
ERα. Notably, the immunocytochemistry assay results 
(Fig. 4) supported these findings by showing decrease of
ERα expression in both of celecoxib and tamoxifen 
treatment.
The activity of celecoxib in the breast cancer
pathophysiology was suggested as the results from tight
crosstalk of COX-2 with ERα pathway [11]. 
Interestingly, our findings presented in this article show
that celecoxib plays an important role in ERα pathway, 
not only because it is a potent COX-2 inhibitor but also
celecoxib is a potent ligand for ERα. Since these 
results emerged from computer-aided drug repurposing
strategy using molecular docking simulations, the
docking pose of celecoxib in the ERα binding pocket 
could provide insight to further design its analogs or
derivatives with better activity towards ERα 
[2,20,23,50].
CONCLUSION
Aided by computational chemistry tools, a potent
anti-inflammatory drug celecoxib was identified as a
potent ligand for ERα. In vitro tests using MTT method
subsequently confirmed that celecoxib is a ligand for
ERα with IC50 (SEM) value of 94.06 (14.30) µM. It is
comparable with the IC50 value of a drug of choice for
breast cancer tamoxifen.
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